Picture of Achieve Life Sciences logo

QUIT — Achieve Life Sciences News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapMomentum Trap

Achieve Life Sciences Inc expected to post a loss of 24 cents a share - Earnings Preview

* Achieve Life Sciences Inc  ACHV.OQ   ACHV.O  is expected
to show
no change in quarterly revenue when it reports  results on May 9
for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Achieve Life Sciences
Inc is
for a loss of 24 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.8%
in the last three months. ​
    * Wall Street's median 12-month price target for Achieve
Life
Sciences Inc is $19.00​, above​ its last closing price of $4.73.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.31       -0.31      -0.26     Beat    17.3
 Sep. 30 2023  -0.37       -0.38      -0.34     Beat    10.2
 Jun. 30 2023  -0.41       -0.42      -0.43     Missed  -2​
 Mar. 31 2023  -0.68       -0.69      -0.50     Beat    27.1
 ​​Dec.        -0.77       -0.83      -0.83     Met     0
 31 2022                                                
 Sep. 30 2022  -1.14       -1.13      -1.35     Missed  -19.8​
 Jun. 30 2022  -0.83       -0.83      -1.08     Missed  -29.5
 Jan. 1 0001   -0.79       -0.81      -0.80     Beat    1.5
 This summary was machine generated May 8 at 01:18 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Achieve Life Sciences

See all news